ClinicalTrials.gg
RecruitingNCT07642024Updated Aug 3, 2026

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

A Phase 2/3 interventional study of BL-B01D1 and Osimertinib in Non-small Cell Lung Cancer, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung — 14 open to participants now, 18 under way, 9 of them phase 3. izalontamab brengitecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
15th of 18
90 · median 417
Started
2026
with 5 others
Phase 2/3
4 of 18
4 open now
Primary completion
2032-12
later than 17 of 17 live
Registered
14th of 18
by date
Lead sponsor
13 of 18
Sichuan Baili Pharmaceutical Co., Ltd.

Among the 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by planned enrollment, is one of 6 that started in 2026, is one of 4 in phase 2/3, reaches primary completion later than 17 of the 17 other live ones, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About izalontamab brengitecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in resectable EGFR-mutant non-small cell lung cancer.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign and agree to comply with the protocol requirements;
  2. Aged ≥18 years and ≤75 years, regardless of gender;
  3. Expected survival time ≥3 months;
  4. Patients with non-small cell lung cancer;
  5. One of the EGFR sensitive mutation types detected in the tumor tissue;
  6. Agree to provide archived primary tumor tissue specimens obtained within 12 months or fresh tissue samples;
  7. Undergo pulmonary function testing within 28 days prior to the first dose;
  8. performance status score of 0 or 1;
  9. No severe cardiac dysfunction;
  10. Organ function levels must meet the required criteria;
  11. Urine protein ≤1+ or \<1000 mg/24h;
  12. For premenopausal women of , a serum pregnancy test must be performed within 7 days before starting treatment, and the serum pregnancy test must exclude pregnancy; patients must not be lactating; all enrolled trial participants must use adequate barrier measures throughout the entire treatment period and for 7 months after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. SCLC, mixed SCLC and NSCLC, or other non-NSCLC pathological types;
  2. Trial participants who subsequently receive only segmentectomy or wedge resection;
  3. Trial participants deemed surgically inoperable by the study center's surgical evaluation;
  4. Undergoing major surgery within 4 weeks prior to the first dose, among others;
  5. Previous receipt of systemic anti-tumor therapy for non-small cell lung cancer other than that for this study, among others;
  6. Receiving long-term systemic therapy with prednisone >10 mg/day within 2 weeks prior to randomization, among others;
  7. History of severe heart disease or cerebrovascular disease;
  8. Prolonged , complete left bundle branch block, etc.;
  9. Any thrombotic event within 6 months prior to screening;
  10. Trial participants with known or suspected interstitial lung disease, among others;
  11. Diagnosis of active malignant tumors within 5 years prior to study randomization;
  12. Hypertension inadequately controlled by two antihypertensive medications;
  13. Trial participants with poorly controlled blood glucose;
  14. Severe infection occurring within 4 weeks prior to study randomization, among others;
  15. Presence of large serous cavity effusion, or serous cavity effusion with symptoms, etc.;
  16. Imaging findings indicating tumor invasion or encasement of the abdomen, chest, etc.;
  17. Severe non-healing wounds, ulcers, or fractures within 4 weeks prior to signing ;
  18. Trial participants with bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent;
  19. Inflammatory bowel disease, history of extensive bowel resection, history of immune-related enteritis, etc.;
  20. History of allergy to the drug, etc.;
  21. History of solid organ transplantation, or allogeneic stem cell transplantation;
  22. Positive for antibodies, active virus infection, or virus infection;
  23. History of severe neurological or psychiatric disorders;
  24. Trial participants planning to receive or having received within 28 days prior to study randomization;
  25. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial due to complications or other circumstances.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    BL-B01D1+Osimertinib

    Participants receive BL-B01D1+Osimertinib in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: BL-B01D1 · Drug: Osimertinib

  • Active comparator
    Osimertinib

    Participants receive Osimertinib in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: Osimertinib

  • Active comparator
    Carboplatin + Pemetrexed or Cisplatin + Pemetrexed

    Participants receive Carboplatin + Pemetrexed or Cisplatin + Pemetrexed in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: Carboplatin · Drug: Pemetrexed · Drug: Cisplatin

Interventions

  • Administration by intravenous infusion for a cycle of 3 weeks.

    Also known as: iza-bren, izalontamab brengitecan, BMS-986507

  • Oral administration for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

  • Administration by intravenous infusion for a cycle of 3 weeks.

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR)

    MPR is defined as the presence of viable tumor tissue ≤10% in the surgical specimen at the time of tumor resection.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Pathologic complete response (pCR)

    pCR is defined as the absence of any residual tumor (lesions) in the primary tumor upon surgical resection.

    Time frame: Up to approximately 24 months

  2. Event-Free Survival (EFS)

    EFS is defined as the time from randomization to the occurrence of any of the following events, whichever occurs first.

    Time frame: Up to approximately 24 months

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the time between the day the subject is randomized and the subject's death.

    Time frame: Up to approximately 24 months

  4. Treatment Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1.

    Time frame: Up to approximately 24 months

  5. Anti-drug antibody (ADA)

    Frequency of anti-BL-B01D1 antibody (ADA) will be investigated.

    Time frame: Up to approximately 24 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2032, 77 months after the start.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 11, 2026
StartActual
Jul 24, 2026
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2032
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07642024
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Jul 24, 2026
Primary completion
Dec 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Aug 3, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
15013238943

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izalontamab brengitecan

Start the discussion